Eikon reports Q3 2026 results, ESMO oncology data and new prostate cancer INDNov 12Quarterly updateAkari Therapeutics PlcAtrium Therapeutics
FDA approves fruquintinib for refractory metastatic colorectal cancerNov 6Regulatory decisionfruquintinib
Charles River raises 2026 guidance after third-quarter organic growth beats forecastNov 4Quarterly updateCharles River Laboratories International, Inc.
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Wave Life Sciences details Q3 2026 progress on WVE-006, WVE-007, WVE-008 pipelineOct 28Quarterly updateBristol Myers SquibbEli LillyUpdated